Medical College, Guangxi University, Nanning 530004, China.
School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Mar Drugs. 2021 Aug 27;19(9):488. doi: 10.3390/md19090488.
Worldwide, 19.3 million new cancer cases and almost 10.0 million cancer deaths occur each year. Recently, much attention has been paid to the ocean, the largest biosphere of the earth that harbors a great many different organisms and natural products, to identify novel drugs and drug candidates to fight against malignant neoplasms. The marine compounds show potent anticancer activity in vitro and in vivo, and relatively few drugs have been approved by the U.S. Food and Drug Administration for the treatment of metastatic malignant lymphoma, breast cancer, or Hodgkin's disease. This review provides a summary of the anticancer effects and mechanisms of action of selected marine compounds, including cytarabine, eribulin, marizomib, plitidepsin, trabectedin, zalypsis, adcetris, and OKI-179. The future development of anticancer marine drugs requires innovative biochemical biology approaches and introduction of novel therapeutic targets, as well as efficient isolation and synthesis of marine-derived natural compounds and derivatives.
全球每年有 1930 万例新增癌症病例和近 1000 万癌症死亡病例。最近,人们对海洋给予了极大的关注,海洋是地球上最大的生物圈,拥有大量不同的生物和天然产物,以寻找对抗恶性肿瘤的新型药物和候选药物。海洋化合物在体外和体内均表现出很强的抗癌活性,而只有少数几种药物被美国食品和药物管理局批准用于治疗转移性恶性淋巴瘤、乳腺癌或霍奇金病。本文综述了几种海洋化合物的抗癌作用和作用机制,包括阿糖胞苷、埃博霉素、马拉瑞林、普雷西丁、曲贝替定、扎利昔普、阿特塞西斯和 OKI-179。抗癌海洋药物的未来发展需要创新的生化生物学方法和引入新的治疗靶点,以及高效的海洋天然产物及其衍生物的分离和合成。